Clinical trial
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian…
NCT00316173 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00316173 |
|---|---|
| Title | Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer |
| Official title | An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 Every 21 Days) HYCAMTIN in Combination With Carboplatin (Day 1 Every 21 Days) as Second-Line Therapy in Subjects With Potentially Platinum-Sensitive Relapsed Ovarian Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Neoplasms, Ovarian |
| Intervention type | Drug |
| Interventions | topotecan, CARBOPLATIN |
| Enrollment | 77 |
| Start date | Mar 1, 2005 |
| Primary completion | Jan 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Apr 20, 2006 |
| Last update posted | Nov 27, 2012 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: